Home » Markets » Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was downgraded by  Zacks Research  from a “buy” score to a “hold” score in a research note released to investors on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm. It focuses on finding and developing small molecule drug prospects to deal with cancer cells. The Firm‘s products under different phases of development consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous other equities research analysts also lately talked about the business. Noble Financial reissued a “acquire” ranking and also provided a $11.00 cost purpose on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 and set a “buy” ranking on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day relocating ordinary cost of $2.90 and also a two-hundred day moving typical cost of $4.16. The business has a market cap of $46.76 million, a P/E ratio of -1.82 as well as a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly incomes results on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) revenues per share for the quarter, covering experts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% as well as a negative internet margin of 8,294.27%. The company had profits of $0.06 million during the quarter, contrasted to the agreement quote of $0.06 million. Throughout the very same quarter in the prior year, the company published ($ 0.45) EPS. As a group, research experts anticipate that Onconova Therapeutics will certainly post -1.18 EPS for the existing year.

A variety of hedge funds have actually just recently dealt shares of ONTX. GSA Funding Allies LLP got a brand-new setting in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Capital Monitoring LP purchased a brand-new position in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC purchased a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC bought a brand-new position in shares of Onconova Therapeutics in the third quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP acquired a new position in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and also various other institutional capitalists own 13.36% of the company’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which engages in the recognition and advancement of oncology therapeutics. It concentrates on discovering as well as creating tiny particle medication prospects to treat cancer cells. The business was founded by Ramesh Kumar as well as E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Obtain a cost-free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

For additional information concerning research offerings from Zacks Investment Research, browse through Zacks.com.

This immediate news alert was produced by narrative scientific research modern technology and economic information from Market in order to give readers with the fastest and also most exact reporting. This story was assessed by Market’s content group before publication. 



Before you think about Onconova Therapeutics, you’ll intend to hear this.

Market keeps an eye on Wall Street’s top-rated and finest executing research experts and the stocks they recommend to their clients daily. Market has recognized the five stocks that cover experts are quietly murmuring to their customers to buy now before the broader market catches on … and Onconova Therapeutics had not been on the listing.

While Onconova Therapeutics currently has a “Buy” ranking amongst experts, premier analysts believe these five stocks are much better gets.